The INCREASE trial brought a glimmer of hope by demonstrating reduction of NT-proBNP levels and increased exercise capacity in patients with ILD-PH who used Treprostinil, a prostacyclin derivative (5). This evidence concerns the gene NPPB and interstitial lung disease.